Chemoimmunotherapy May Be Safe, Effective for Prostate Cancer

Share this content:
Combination angiogenesis inhibition can be safely administered with supportive measures in metastatic castration-resistant prostate cancer.
Combination angiogenesis inhibition can be safely administered with supportive measures in metastatic castration-resistant prostate cancer.

Combination angiogenesis inhibition can be safely administered with appropriate supportive measures and potentially provide clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC), a study published online ahead of print in BJU International has shown.1

Because preclinical data have demonstrated the significance of angiogenesis in prostate cancer, previous clinical trials have assessed using angiogenesis inhibitors in combination with docetaxel, but with limited success. Therefore, researchers sought to evaluate multiple antiangiogenic therapies together as a means to reduce resistance and optimize this therapeutic strategy.

For the open-label, phase 2 trial, researchers enrolled 63 patients with mCRPC. All patients received docetaxel 75 mg/m2 intravenously and bevacizumab 15 mg/kg intravenously on day 1 of each 21-day cycle, in combination with dose-escalated lenalidomide and prednisone 10 mg daily. Patients also received supportive measures including prophylactic pegfilgrastim and enoxaparin.

Results showed that of the 61 evaluable patients, 93%, 90%, and 54% had prostate-specific antigen (PSA) declines > 30%, > 50%, and > 90%, respectively. Researchers also found that 24 patients had a confirmed radiographic partial response and median overall survival was 24.6 months.

RELATED: Non-recommended Screenings for Prostate, Breast Cancer May Be Common in Older Adults

With respect to safety, 46% of patients had grade 4 neutropenia, 32% had grade 3 anemia, and 11% had grade 3 thrombocytopenia; however, toxicities were manageable and serious infections were rare. Other frequently reported non-hematologic grade 3 adverse events included fatigue (10%) and diarrhea (10%). The most common grade 2 adverse events were anorexia, weight loss, constipation, osteonecrosis of the jaw, rash, and dyspnea.

The authors noted that randomized trials are warranted to confirm the safety and efficacy of this combination antiangiogenic regimen.

Reference

  1. Madan RA, Karzai FH, Ning Y-M, et al. Phase II trial of docetaxel, bevacizumab, lenalidomide, and prednisone in patients with metastatic castration-resistant prostate cancer [published online ahead of print January 18, 2016]. BJU Int. doi: 10.1111/bju.13412.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters